Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis

← catalyst calendar

NCT03042104

Sponsored by Edwards Lifesciences (industry) · EW — their whole pipeline →.

Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
901actual
Sites
77
Countries
Canada, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2017-07-12actualWhen the study began enrolling
Primary completion2024-03-31actualThe date the last participant is measured for the primary outcome — the readout window
Study completionMar 2032estimatedThe whole study's end, after follow-up
First posted2017-02-03estimatedWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2024-05-13actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Heart Diseases
  • Aortic Stenosis, Severe

Intervention

  • Device: Edwards SAPIEN 3 / SAPIEN 3 Ultra THV — also filed as SAPIEN 3, SAPIEN 3 Ultra

Primary outcome

what the primary-completion date above is the date OF
All-cause death, all stroke, and unplanned cardiovascular hospitalization
measured When all patients have reached 2-year follow-up

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · EW's whole pipeline · Catalyst calendar · Every registered study · What changed